|
9th Influenza Conference 2023
Scientific highlights of the 9th ESWI Influenza Conference
With promising developments in the field of respiratory viral infections, the conference sessions covered hot topics on seasonal, pandemic, and zoonotic influenza viruses, as well as other respiratory viruses such as RSV and SARS-CoV-2.
ECDC on Air podcast. Why Monitoring Respiratory Viruses Matters?
In this episode, ECDC expert on respiratory viruses, Nick Bundle, gives the lowdown on the European Respiratory Virus Surveillance Summary (ERVISS), a new surveillance tool which presents weekly data on influenza, SARS-CoV-2 and RSV.
In Utero Exposure to Maternal COVID-19 Vaccination and Offspring Neurodevelopment at 12 and 18 Months
Uptake of COVID-19 vaccines among pregnant individuals was hampered by safety concerns around potential risks to unborn children.
SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase
XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1
COVID-19 vaccines have recently been updated to specifically encode or contain the spike protein of the SARS-CoV-2 XBB.1.5 subvariant.
Perception of government performance during COVID-19 not linked to death rate.
People living in the United States are more likely to report that their government handled the COVID-19 pandemic ‘well’ than any other G7 nation despite having the highest death rate, according to a new report from the Global Listening Project.
Article
News
Scientific Papers
Effect of second booster vaccinations and prior infection against SARS-CoV-2 in the UK SIREN healthcare worker cohort
The protection of fourth dose mRNA vaccination against SARS-CoV-2 is relevant to current global policy decisions regarding ongoing booster roll-out.
Mucosal and systemic immune correlates of viral control after SARS-CoV-2 infection challenge in seronegative adults
Human infection challenge permits in-depth, early, and pre-symptomatic characterization of the immune response, enabling the identification of factors that are important for viral clearance.
WHO Information Network for Epidemics update on COVID-19
Latest information about circulation, impact and what is needed to prevent infections, severe disease, post-COVID-19 condition and deaths.
Is it bad, is it good, or is IgG4 just misunderstood?
Repeated doses of mRNA vaccines for COVID-19 result in increased proportions of anti-spike antibodies of the IgG4 subclass.
Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years
Bivalent mRNA COVID-19 vaccines were recommended in the US for children and adolescents aged 12 years or older on September 1, 2022, and for children aged 5 to 11 years on October 12, 2022.
Vaccination coverage in the EU/EEA during autumn 2023 campaigns
Nearly 20 million people aged 60 years and above received COVID-19 vaccines during the autumn/winter campaign in the EU/EEA, according to a new report from the European Centre for Disease Prevention and Control (ECDC).